Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19387236 | 0.95 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL13310847 | 0.95 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL10000268 | 0.95 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL10502311 | 0.94 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL14295792 | 0.89 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL13402170 | 0.86 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL9128951 | 0.86 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL22529465 | 0.85 | NQO1 (0.54) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL10000271 | 0.84 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL14295785 | 0.84 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250338-A1 | COMPOUND AND LIQUID CRYSTAL COMPOSITION | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-08-10 | — | — | US | disclosed |
| US-8512820-B2 | Organic ionic phenylpyrimidine compounds and displays formed thereof | CITIZEN FINETECH MIYOTA CO., LTD. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-20130200306-A1 | SYNERGISTIC HOST-GUEST INTERACTIONS IN FLC MIXTURES FOR INCREASED POLARIZATION AND DECREASED SWITCHING SPEED | MICRON TECHNOLOGY, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120319044-A1 | ORGANIC IONIC PHENYLPYRIMIDINE COMPOUNDS AND DISPLAYS FORMED THEREOF | CITIZEN FINEDEVICE CO., LTD. (JP) | 2012-12-20 | — | — | US | disclosed |
| US-8158020-B2 | Liquid crystal element, optical path deflecting element, and image displaying apparatus | RICOH COMPANY, LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120319044-A1 | ORGANIC IONIC PHENYLPYRIMIDINE COMPOUNDS AND DISPLAYS FORMED THEREOF | PNP, PNPO, TYMP | NPC1 4801/4885RAB9A 4681/4885SMN1; SMN2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.